$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017
[Report Updated: 01-10-2017]

Published by Current Partnering: 01 Oct 2017 | 119440 | In Stock
Related Topics: Abbott , AstraZeneca , Lilly , Novartis , Pfizer , Roche

Introduction

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report.


The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


This report provides details of the latest discovery agreements announced in the healthcare sector.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all discovery stage partnering deals announced since 2010 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.


Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.


Chapter 5 provides a review of discovery stage deal making since 2010. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.


Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.


Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 8 provides a comprehensive listing of the top 50 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.


Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2010.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2010.


In addition, a comprehensive appendix of all discovery deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.


Key benefits


Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 provide the reader with the following key benefits:


In-depth understanding of discovery stage deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of discovery stage agreements with numerous real life case studies

Insight into the terms included in a discovery stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 include:


Trends in discovery stage dealmaking in the biopharma industry since 2010

Analysis of discovery stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life discovery stage deals

Access to over 3,000 discovery stage deals

The leading discovery stage deals by value since 2010

Most active discovery stage dealmakers since 2010

The leading discovery stage partnering 2010


In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017, the available contracts are listed by:


Company A-Z

Headline value

Stage of development at signing

Deal type

Specific therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report provides comprehensive access to available deals and contract documents for over 3,000 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 [Report Updated: 01-10-2017]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Why do companies partner at discovery stage?

    2.1. Introduction

    2.2. The role of discovery stage partnering

    2.2.1. In-licensing at discovery stage

    2.2.2. Out-licensing at discovery stage

    2.3. Difference between discovery, preclinical and clinical stage deals

    2.4. Reasons for entering into discovery stage partnering deals

    2.4.1. Licensors reasons for entering discovery stage deals

    2.4.2. Licensees reasons for entering discovery stage deals

    2.5. The future of discovery stage partnering deals

    Chapter 3 – Discovery stage deal strategies and structure

    3.1. Introduction

    3.2. At what stage do companies partner?

    3.2.1. Partnering early in pharmaceutical/biotech

    3.2.1.1. Discovery and preclinical stage partnering case studies

    3.2.1.1.a. Case study: LEO Pharma - 4SC

    3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

    3.2.1.1.c. Case study: Incyte – Agenus Bio

    3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

    3.2.2. Partnering later in pharmaceutical/biotech

    3.2.2.1. Clinical stage partnering case studies

    3.2.2.1.a. Case study: Servier – GeNeuro

    3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

    3.2.2.1.c. Case study: AstraZeneca - Ardelyx

    3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

    3.3. Early and later stage partnering – a risk/cost comparison

    3.4. What do companies spend on discovery, preclinical and clinical stage partnering?

    3.5. Pure versus multi-component partnering deals

    3.6. Pure licensing agreement structure

    3.6.1. Example pure licensing agreements

    3.6.1.a. Case study : Pfizer – Spark Therapeutics

    3.6.1.b. Case study : Contrafect – Trellis Bioscience

    3.7. Multicomponent discovery stage partnering agreements

    3.7.1.a. Example multicomponent early stage clauses

    3.7.1.a. Case study: Tracon – Boehringer Ingelheim – Macrogenics

    3.7.1.b. Case study: Fibrocell Science – Intrexon

    Chapter 4 – Discovery stage partnering payment strategies

    4.1. Introduction

    4.2. Discovery stage payment strategies

    4.3. Payment options

    4.3.1. Headline values

    4.3.2. Upfront payments

    4.3.2.1. Conditionality of upfront payments

    4.3.3. Loans

    4.3.4. Convertible loans

    4.3.5. Equity

    4.3.6. R&D funding

    4.3.7. Licensing fees

    4.3.8. Milestone payments

    4.3.9. Royalty payments

    4.3.9.1. Issues affecting royalty rates

    4.3.9.2. Royalties on combination products

    4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

    4.3.9.3. Guaranteed minimum/maximum annual payments

    4.3.9.4. Royalty stacking

    4.3.9.5. Royalties and supply/purchase contracts

    4.3.10. Quids

    4.3.11. Option payments

    Chapter 5 – Trends in discovery stage deal making

    5.1. Introduction

    5.2. Discovery stage partnering over the years

    5.2.1. Attributes of discovery deals

    5.3. Discovery stage partnering by deal type

    5.4. Discovery stage partnering by disease type

    5.5. Partnering by discovery stage technology type

    5.6. Discovery stage partnering by most active company since 2010

    Chapter 6 – Payment terms for discovery stage partnering

    6.1. Introduction

    6.2. Guidelines for discovery stage payment terms

    6.2.1. Upfront payments

    6.2.2. Milestone payments

    6.2.3. Royalty payments

    6.3. Discovery stage payment terms – deal data analysis

    6.3.1. Public data

    6.3.2. Survey data

    6.4. Payment terms analysis

    6.4.1. Discovery stage headline values

    6.4.2. Discovery stage deal upfront payments

    6.4.3. Discovery stage deal milestone payments

    6.4.4. Discovery stage royalty rates

    Chapter 7 – Leading discovery stage deals

    7.1. Introduction

    7.2. Top discovery stage deals by value

    Chapter 8 – Top 50 most active discovery stage dealmakers

    8.1. Introduction

    8.2. Top 50 most active discovery stage dealmakers

    Chapter 9 – Discovery stage partnering contracts directory

    9.1. Introduction

    9.2. Discovery stage deals with contracts 2010 to 2017

    Chapter 10 – Discovery stage deal making by development stage

    10.1. Introduction

    10.2. Deals by discovery stage

    Appendices

    Appendix 1 – Discovery stage dealmaking by companies A-Z

    Appendix 2 – Discovery stage dealmaking by industry sector

    Appendix 3 – Discovery stage dealmaking by stage of development

    Appendix 4 – Discovery stage dealmaking by therapy area

    Appendix 5 – Discovery stage dealmaking by technology type

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from CurrentPartnering

    Table of figures

    Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

    Figure 2: Agreements signed by phase of development (2010-2017), % of all deals where stage disclosed

    Figure 3: Components of the pure licensing deal structure

    Figure 4: Payment options for discovery stage partnering deals

    Figure 5: Issues affecting royalty rates

    Figure 6: Discovery stage partnering frequency since 2010

    Figure 7: Discovery stage partnering by deal type since 2010

    Figure 8: Discovery stage partnering by disease type since 2010

    Figure 9: Discovery stage partnering by technology type since 2010

    Figure 10: Top 50 most active discovery stage dealmakers since 2010

    Figure 11: Review of median upfront payments for discovery stage deals

    Figure 12: Review of median milestone payments for discovery stage deals

    Figure 13: Review of median royalty payments for discovery stage deals

    Figure 14: Discovery stage deals with a headline value

    Figure 15: Discovery stage deals with an upfront value

    Figure 16: Discovery stage deals with a milestone value

    Figure 17: Discovery stage deals with a royalty rate value

    Figure 18: Top discovery stage deals that exceeds billion in deal value since 2010

    Figure 19: Most active discovery stage dealmakers since 2010

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

119440 | CP2056

Number of Pages

1000

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 report. T...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Phenotypic Drug Discovery Trends 2015
HTStec's Phenotypic Drug Discovery Trends 2015 report was published on 21 September 2015. This 60 pa...
21 Sep 2016 by HTStec USD $2,000 More Info
CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016
HTStec's CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016 report was published on 2 March 201...
02 Mar 2016 by HTStec USD $2,000 More Info
Horizon Discovery Group Plc (HZD) - Medical Equipment - Deals and Alliances Profile
SummaryHorizon Discovery Group plc (Horizon Discovery) is a biotechnology company that provides rese...
25 Feb 2016 by Global Data USD $250 More Info
Health Discovery Corporation (HDVY) - Medical Equipment - Deals and Alliances Profile
SummaryHealth Discovery Corporation (HDC) is a biotechnology company that provides medicine and biom...
25 Feb 2016 by Global Data USD $250 More Info
Advanced Marker Discovery, S.L. - Medical Equipment - Deals and Alliances Profile
SummaryAdvanced Marker Discovery, S.L. (Amadix) is a biotechnology company that develops diagnostic ...
23 Feb 2016 by Global Data USD $250 More Info
Health Discovery Corporation (HDVY) - Financial and Strategic SWOT Analysis Review
SummaryHealth Discovery Corporation (HDC) is a biotechnology company that provides medicine and biom...
09 Jan 2016 by Global Data USD $300 More Info
Induced Pluripotent Stem Cells In Research & Drug Discovery Trends 2015
HTStec's Induced Pluripotent Stem Cells In Research & Drug Discovery Trends 2015 report was publishe...
01 Dec 2015 by HTStec USD $2,000 More Info
Health Discovery Corporation (HDVY) - Financial and Strategic SWOT Analysis Review
SummaryHealth Discovery Corporation (HDC) is a biotechnology company that provides medicine and biom...
08 Nov 2015 by Global Data USD $300 More Info
Health Discovery Corporation (HDVY) - Medical Equipment - Deals and Alliances Profile
SummaryHealth Discovery Corporation (HDC) is a biotechnology company that provides medicine and biom...
16 Oct 2015 by Global Data USD $250 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 [Report Updated: 01-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)